Fig. 3

Mean fluorescent intensity of total sarcolemmal α-sarcoglycan (a) and β-dystroglycan (b) at baseline and following 48 weeks therapeutic intervention with golodirsen. Each data point represents the average intensity for each patient at each time point. Changes in α-sarcoglycan (c) and β-dystroglycan (d) sarcolemmal fluorescent intensity for each patient from baseline to 48 weeks. α-Sarcoglycan (e) and β-dystroglycan (f) fluorescent intensity after 48 weeks treatment in regions of dystrophin positive and dystrophin negative sarcolemma. Percentage change in α-sarcoglycan (g) and β-dystroglycan (h) intensity from dystrophin negative to dystrophin positive sarcolemma at both baseline and 48 week time points